Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024

Published

ORION CORPORATION PRESS RELEASE 29 January 2024 at 15.00 EET

Orion publishes Financial Statement Release for 2023 and holds a webcast on 13 February 2024

Orion will publish Financial Statement Release for 2023 on Tuesday, 13 February 2024 at approximately 12.00 noon EET. The release and related presentation material will be available on the company’s website at www.orion.fi/en/investors after publishing.

Webcast and conference call

A webcast and a conference call for analysts, investors and media representatives will be held on Tuesday, 13 February 2024 at 13.30 EET.

A link to the live webcast is available on Orion's website at www.orion.fi/en/investors. A recording of the event will be available on the website later the same day.

Confenrence call can be joined by registering through the following link: https://palvelu.flik.fi/teleconference/?id=5008942

Phone numbers and the conference ID to access the conference will be provided after the registration. In case you would like to ask a question during the conference, please dial *5 on your telephone keypad to enter the question queue.

Questions can also be presented in writing through the question form of the webcast.

Silent period

The silent period preceding the publication is ongoing and continues until the disclosure.

                                                Contact person:Tuukka Hirvonen, Investor Relations, Orion Corporationtel. +358 10 426 2721

Publisher:Orion CorporationCommunicationsOrionintie 1A, FI-02200 Espoo, Finlandwww.orion.fi

Orion is a globally operating Finnish pharmaceutical company – a builder of well-being. We develop, manufacture and market human and veterinary pharmaceuticals and active pharmaceutical ingredients. Orion has an extensive portfolio of proprietary and generic medicines and self-care products. The core therapy areas of our pharmaceutical R&D are oncology and pain. Proprietary products developed by Orion are used to treat cancer, neurological diseases and respiratory diseases, among others. Orion's net sales in 2022 amounted to EUR 1,341 million and the company had about 3,500 employees at the end of the year. Orion's A and B shares are listed on Nasdaq Helsinki.

In This Story

ORINY